Personalized Medicine in Acromegaly: The ACROFAST Study
2024

Personalized Medicine in Acromegaly: The ACROFAST Study

Sample size: 85 publication 10 minutes Evidence: high

Author Information

Author(s): Marques-Pamies Montserrat, Gil Joan, Sampedro-Nuñez Miguel, Valassi Elena, Biagetti Betina, Giménez-Palop Olga, Hernández Marta, Martínez Silvia, Carrato Cristina, Villar-Taibo Rocío, Araujo-Castro Marta, Blanco Concepción, Simón-Muela Inmaculada, Simó-Servat Andreu, Xifra Gemma, Vázquez Federico, Pavón Isabel, Rosado José Antonio, García-Centeno Rogelio, Zavala Roxana, Hanzu Felicia Alexandra, Mora Mireia, Aulinas Anna, Vilarrasa Nuria, Librizzi Soledad, Calatayud María, de Miguel Paz, Alvarez-Escola Cristina, Picó Antonio, Salinas Isabel, Fajardo-Montañana Carmen, Cámara Rosa, Bernabéu Ignacio, Jordà Mireia, Webb Susan M, Marazuela Mónica, Puig-Domingo Manel

Primary Institution: Instituto de Salud Carlos III

Hypothesis

The personalized protocol would be more efficient for medical therapy of acromegaly compared to standard treatment.

Conclusion

Personalized medicine is feasible and allows a higher number of patients to achieve control in a shorter period of time.

Supporting Evidence

  • More patients in the personalized protocol achieved hormonal control compared to those in the control group (78% vs 53%).
  • Patients from the personalized arm were controlled in a shorter period of time.
  • The hazard ratio for achieving hormonal control adjusted by age and sex was 2.53.

Takeaway

This study shows that using a personalized approach to treat acromegaly helps more patients get better faster than the usual method.

Methodology

A prospective trial comparing personalized treatment based on biomarkers to standard treatment in 21 university hospitals over 12 months.

Potential Biases

Potential bias due to non-randomized design and exclusion of patients.

Limitations

The study was not randomized, and there were more exclusions in the personalized group.

Participant Demographics

Participants included adults aged 18-80 with acromegaly, both newly diagnosed and postsurgical noncured cases.

Statistical Information

P-Value

p<0.05

Confidence Interval

CI, 1.30-4.80

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1210/clinem/dgae444

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication